|
Kiểu hiển thị:
|
|
Found 1 documents that match the search criteria.
|
Le Thi Thanh Xuan, Quan Long Hoang, Nhung Thi Kim Ta, Quan Thi Pham, Thao Thanh Nguyen, Huong Thi Mai Phan, Thanh Van Nguyen, Ha Thi Thanh Le, Nam Thuy Nguyen, Linh Dieu Hoang, Phuong Thi Huyen Luong, Lien Hong An, Thu Ha Nguyen, Thinh Thi Nguyen, Hien Thuy Nguyen, Huong Thu Le, Doanh Qu
Frontiers in Tropical Diseases
Rationale: To prevent and control the COVID-19 pandemic, the biggest immunization campaign in history had been deployed worldwide. Therefore, it is important to inform the adverse events following immunization (AEFI) to populations. Objectives: To prevent vaccine hesitancy, this study focused on finding the common AEFI with the COVID-19 Comirnaty vaccine (Pfizer-BioNTech) among participants aged 18 and above and related factors in Hanoi, Vietnam. Methods: A cross-sectional study was carried out to collect participants’ data and AEFI after being vaccinated at Hanoi Medical University, Vietnam, in 2021. Logistic regression was utilized for analyzing the correlated factors of AEFI. Results: We recruited a random sample of 820 participants who received both basic doses of Pfizer vaccine in September and October 2021. The proportion of AEFI after the first dose, second dose, and both doses of Pfizer vaccine was 24.4%, 64.2%, and 18.5%, respectively. AEFI mostly appeared within 1 day and lasted for 1 to 2 days. The AEFI were more common in females (OR=1.7; 95% CI=1.25–2.29) and younger age groups (OR=1.9; 95%CI=1.37–2.58). History of allergy, allergic diseases, chronic diseases, and occupations were not statistically significant with AEFI Conclusion: Our findings indicated that the COVID-19 Comirnaty vaccine
is safe to be injected. Gender and age group are important factors
influencing AEFI.
|